Videos
Early Relapsed Multiple Myeloma: What’s Changing in 2025 | Research Breakthroughs from ASCO & EHA
Are you or a loved one navigating a multiple myeloma relapse after one to three prior treatments?
In this video, Dr. Joseph Mikhael, Chief Medical Officer of the International…
Videos
Dr. Joseph Mikhael's presentation reveals a transformative period in multiple myeloma treatment, with June 2025 marking unprecedented breakthroughs across the disease spectrum. The research demonstrates a paradigm shift toward precision medicine, where MRD (minimal residual disease) negativity is…
Videos
Newly Diagnosed Multiple Myeloma: What’s Changing in 2025? | ASCO & EHA
Dr. Joseph Mikhael (IMF Chief Medical Officer) breaks down the most important updates from ASCO and EHA for newly diagnosed multiple myeloma patients. Learn how your first treatment can shape long-term outcomes…
Videos
DOWNLOAD SLIDES
News Article
The International Myeloma Foundation Mourns the Loss of Accomplished Attorney and Longtime Board Member Benson Klein
STUDIO CITY, CA, July 29, 2025—Today, the International Myeloma Foundation (IMF) announces with great sadness the passing of our beloved and…
Videos
Exploring Linvoseltamab (LINVO) and Carfilzomib (CFZ) combination in relapsed/refractory multiple myeloma (RRMM) via LINKER-MM2 trial. Assessing safety, efficacy, and pharmacokinetics with promising initial outcomes: high response rates (ORR 91-100%), manageable toxicity (neutropenia,…
News Article
EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma
On Friday, July 25, the European Union (EU) approved Sarclisa (isatuximab-irfc) to be used "in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for…
Videos
The ADVANCE study compared DKRd (daratumumab, carfilzomib, lenalidomide, dexamethasone) with KRd (carfilzomib, lenalidomide, dexamethasone) in newly diagnosed multiple myeloma patients. Primary endpoint was MRD negativity, showing DKRd significantly outperformed KRd (59% vs 36%). Safety profiles…
News Article
July 24, 2025—According to a press release from GSK, Blenrep (belantamab mafodotin) has been approved "in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at…
Videos
Answering Your Myeloma Clinical Trial Questions
Thinking About a Myeloma Clinical Trial? Get Real Answers from Experts and Patients
Join Dr. Joseph Mikhael (Chief Medical Officer, International Myeloma Foundation), long-term survivor Thomas Goode, and Brian McMahon (Founder of SparkCures) as…
Videos
Relapsed Multiple Myeloma What Every Patient Needs to Know Relapsed multiple myeloma can bring new challenges, but understanding your options can make a difference. In this video, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, answers the top Googled…
U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma
News Article
FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma
July 23, 2025—According to a press release from GSK, "the US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA…
News Article
Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple Myeloma
July 23, 2025—According to a press release from GSK, "Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and…
Videos
PERSEUS (NCT03710603) compared DVRd vs VRd in transplant-eligible newly diagnosed multiple myeloma. DVRd significantly improved PFS, CR rates, and MRD negativity. Sustained MRD negativity (≥12 months) with DVRd correlated with superior 48-month PFS, supporting its NCCN recommendation.
…
News Article
European Commission Approves First Treatment for High-Risk Smoldering Multiple Myeloma
July 23, 2025—According to a press release from Johnson & Johnson, "the European Commission (EC) has approved a new indication for Darzalex® (daratumumab) subcutaneous (SC) formulation…
Videos
The IRAKLIA trial (NCT05405166) compared subcutaneous (SC) vs intravenous (IV) administration of Isatuximab (Isa) combined with Pomalidomide (Pd) in relapsed/refractory multiple myeloma (RRMM). Conducted with an investigational wearable injector, results demonstrated comparable efficacy (71%…
News Article
ODAC votes against belantamab mafodotin in combination with bortezomib and dexamethasone (3-5), and in combination with pomalidomide and dexamethasone (1-7); FDA extends review period for Blenrep, PDUFA action date moved to October 23, 2025
On Thursday, July 17, the Oncologic Drugs…
Videos
Anitocabtagene autoleucel (anito-cel), an anti-BCMA CAR T-cell therapy, is evaluated in the iMMagine-1 Phase 2 trial for relapsed/refractory multiple myeloma (RRMM). The study aims to assess safety and efficacy in heavily pretreated patients. Results show a high overall response rate (97%) with…
Videos
The phase III IsKia trial evaluated Isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) vs KRd for transplant-eligible NDMM patients. IsaKRd significantly increased MRD negativity rates post-induction and consolidation. Light consolidation maintained 10-6 sustMRD negativity advantage,…
Videos
CARTITUDE-1 evaluated cilta-cel in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients with historically poor outcomes. At 60.3 months follow-up, 33% remained progression-free ≥5 years post-infusion, showing significant biomarker correlations and durable responses. Median…
Videos
Top 10 Myeloma Breakthroughs from ASCO & EHA: Frontline Therapy, Early & Late Relapse, and CAR T-cell Insights
Interested in the latest breakthroughs presented at ASCO and EHA this year? Dr. Joseph Mikhael, IMF Chief Medical Officer, condenses the top 10 multiple myeloma research…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the July 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Multiple Myeloma Q&A: Why Diagnosis Can Take 12+ Months, MGUS, Costs & FDA News
Answering your myeloma questions! Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, tackles the most pressing concerns from patients and care partners—from why…
News Article
The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research
STUDIO CITY, CA, July 10, 2025 — The International Myeloma Foundation (IMF) is proud to announce the 30th…
News Article
European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)
July 8, 2025—According to a press release from Oncopeptides, "its drug Pepaxti has been included…
Videos
Description:
Learn about bispecifics in multiple myeloma.
Module Objectives:
Review important concepts for bispecifics use in mutiple myeloma
Highlight important nursing considerations for patient education
Learn about the…
Page
What Is Lynozyfic (linvoseltamab-gcpt)?LYNOZYFIC™ (also known as linvoseltamab-gcpt , the generic drug name) is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. In July 2025, the U.S. FDA granted accelerated approval of Lynozyfic for the…
IMF Person
Kristina is a Certified Meeting Professional (CMP) with a decade of experience orchestrating diverse events, from large-scale corporate and medical conferences to intimate rare disease family gatherings and weddings. Her career began in-house with prominent associations like the New York State Bar…
Videos
Palliative Care in Multiple Myeloma: What It Really Means for Patients and Families
What is palliative care in multiple myeloma—and why is it so important? Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, explains the role of palliative care in under a…
News Article
July 2, 2025—According to this press release from Regeneron Pharmaceuticals Inc., the "U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have…
News Article
The International Myeloma Foundation Proudly Announces we have completed and finalised the EMA-CHMP Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials
Another…
Videos
DOWNLOAD SLIDES
News Article
FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) Program for Certain Autologous CAR T-cell Therapies
July 1, 2025—According to this press release from the U.S. Food and Drug Administration, "The U.S. Food and Drug Administration announced today that it has eliminated the…
News Article
U.S. FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)
June 30, 2025—According to a June 26th press release from Bristol Myers Squibb (BMS), "the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell…
Videos
Elranatamab (ELRA), a BCMA-CD3 bispecific antibody, combined with lenalidomide ± daratumumab, showed promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients. MagnetisMM-6 Phase 3 trial (NCT05623020) evaluated ELRA in dose level G (DLG),…
News Article
June 27, 2025—In this article, Oncology Nursing News sat down with the International Myeloma Foundation's Interim CEO and Senior Vice President of Strategic Planning, Diane Moran, RN, MA, EdM, to discuss how healthcare providers, particularly nurses, contribute to transitioning myeloma care…
Videos
Talquetamab Side Effects: Managing Taste Loss, Hair & Nail Changes in Myeloma New bispecific antibodies like TALVEY® (talquetamab-tgvs) unlock a powerful way to attack multiple myeloma via the GPRC5D target—but they can cause unique side effects.In this Myeloma Made Simple episode, Dr.…
News Article
Led by IMF Director of Public Policy and Advocacy Danielle Doheny, the Coalition to Improve Access to Cancer Care (CIACC) applauds the reintroduction of the bipartisan bill.
WASHINGTON D.C. — On Tuesday, June 24, a group of bipartisan lawmakers —…
Videos
NEXICART-2 evaluates NXC-201 CAR-T in RR AL Amyloidosis, focusing on safety and efficacy outcomes. Results indicate rapid, deep hematologic responses with manageable toxicities, suggesting NXC-201 as a promising treatment.
Key Points:
Research Problem/Question:…
News Article
European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma
June 23, 2025—According to a press release from Sanofi, "The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…
News Article
Darzalex (daratumumab) Receives Positive Opinion from European CHMP for High-Risk Smoldering Multiple Myeloma Patients
According to a press release from Johnson & Johnson, "the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the…
Videos
JNJ-5322, a next-generation bispecific antibody, targets BCMA and GPRC5D via T-cell redirection in patients with relapsed/refractory multiple myeloma. The phase 1 trial (NCT05652335) explored dose escalation up to 300 mg Q4W, identifying 100 mg Q4W as the recommended phase 2 dose. Results indicate…
Videos
Why 4 Drugs Work Better in Myeloma: Quadruplet Therapy Explained | Myeloma Made Simple
Should myeloma patients start with 2, 3, or 4 drugs? In this Myeloma Made Simple episode, Dr. Joseph Mikhael breaks down why quadruplet therapy (4 drug combination therapy) is now the new standard of…